Inclusion Criteria:
Project 1: HealthKit
- Individuals who meet at least one of the following criteria:
- Diagnosis of new onset early-stage (I-III), low-grade (I-II), or locally advanced solid tumor
- Historical diagnosis of primary invasive solid tumor
- Diagnosis of metastatic (stage IV) or high-grade (III-IV) disease
- Enrolled onto an investigational trial in the EDD Service
- Seen in the MSK UCC from 2021 and onwards
- Completion of Survivorship Patient Self-Assessment
- Adult without a history of cancer <50 years of age
- Adult without a history of cancer ≥ 50 years of age
- ≥18 years old
- Own an Apple iPhone or Android with valid operating software
- Self-reported "very well" comprehension of written and verbal English language
- Willing and able to provide informed consent and HIPAA authorization for the release of personal health information
Project 2: DigIT-Ex
Individuals who meet one of the following criteria:
- Patients at MSK who are:
- Scheduled to undergo any type of BMT (Cohort 1)
- Diagnosed with new onset AML and scheduled to initiate antineoplastic therapy (Cohort 2)
- Scheduled to undergo any surgery for prostate cancer (Cohort 3)
- Scheduled to undergo any lung cancer surgery (Cohort 4)
- Scheduled to undergo TNT for locally advanced rectal cancer (Cohort 5)
- Scheduled to initiate androgen deprivation therapy for at least 12 months and has one of the following prostate cancer diagnoses (Cohort 6):
- High risk/very high localized, locally advanced,
- Biochemically recurrent prostate cancer
- Treatment naïve, low-volume metastatic prostate cancer
- Scheduled Scheduled to undergo chemotherapy for metastatic pancreatic cancer (Cohort 7)
- Receiving outpatient care at Memorial Sloan Kettering Cancer Center (MSK)(Cohort 10)
- Diagnosed with metastatic cancer to bone (Cohort 10)
- Scheduled for non-emergent orthopaedic surgery to stabilize lower-extremity bone metastases (Cohort 10)
- Able to undergo at least 5 consecutive days of preoperative monitoring prior to surgery (Cohort 10)
- Have had a CT scan including the L3 vertebral level within 3 months before surgery (used to assess skeletal muscle mass and sarcopenia) (Cohort 10)
- Have a ≥50% predicted likelihood of 6-month postoperative survival, as estimated by the PATHFx clinical decision-support tool (Cohort 10
- Individuals without cancer <50 years of age (Cohort 8)
- Individuals without cancer ≥50 years of age (Cohort 9)
- 18 to 90 years old at the time of consent
- Willing and able to download the Withings Health Mate app onto their personal mobile device
- Willing to provide mobile digital physiological data for a period of at least six months to a maximum of one year following consent for Cohorts 1-9, and 4 months following consent for Cohort 10.
- Willing to provide informed consent
Exclusion Criteria:
Project 1: HealthKit
- Unable or unwilling to successfully export and /or share physiological data
Project 2: DigIT-Ex
- Unable or unwilling to appropriately use digital platforms or devices
- Require a wheelchair for ambulation (Cohort 10)
- Are undergoing stabilization surgery for a primary bone tumor (rather than metastatic disease) (Cohort 10)